alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
| (logo) WELLS FARGO | Corporate Trust ServicesMAC R1204-0109062 Old Annapolis RoadColumbia, MD 21045Tel: 410 884 2000 Fax: 410 715 2380 |
|--------------------|-------------------------------------------------------------------------------------------------------------------|

 

 

Credit Suisse First Boston Mortgage Securities Corp.

11 MADISON AVE

NEW YORK, New York 10010-3643

 

 

RE: Annual Statement of Compliance for Credit Suisse First Boston Mortgage Securities Corp., Commercial Mortgage Pass-Through Certificates Series 2015-C2

 

Per the Pooling and Servicing Agreement dated as of May 1, 2015 (the "Agreement"), the undersigned, a duly authorized officer of Wells Fargo Bank, N.A., as Certificate Administrator ("Wells Fargo"), hereby certifies as follows as of and for the year ending December 31, 2015 (the "Reporting Period"):

 

(a) A review of Wells Fargo's activities during the Reporting Period and of its performance under the Agreement has been made under such officer's supervision; and

 

(b) To the best of such officer's knowledge, based on such review, Wells Fargo has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.

 

 

February 29, 2016

 

 

/s/ Brian Smith

BRIAN SMITH

Vice President

 

 

Wells Fargo Bank, N.A.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5880 Anesthetic vaporizer. ( a ) *Identification.* An anesthetic vaporizer is a device used to vaporize liquid anesthetic and deliver a controlled amount of the vapor to the patient.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.3250 Specimen transport and storage container. ( a ) *Identification.* A specimen transport and storage container, which may be empty or prefilled, is a device intended to contain biological specimens, body waste, or body exudate during storage and transport in order that the matter contained therein can be destroyed or used effectively for diagnostic examination. If prefilled, the device contains a fixative solution or other general purpose reagent to preserve the condition of a biological specimen added to the container. This section does not apply to specimen transport and storage containers that are intended for use as part of an over-the-counter test sample collection system for drugs of abuse testing.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180 of this chapter, with respect to general requirements concerning records, and § 820.198 of this chapter, with respect to complaint files.
[54 FR 47206, Nov. 13, 1989, as amended at 65 FR 2310, Jan. 14, 2000; 65 FR 18234, Apr. 7, 2000]
Rev 0 (9/08) 

## Com **ments i**  **n Response to “**  **Final r**  **ule; r**  **equest for c**  **om ments**  **”**
**Docket: FAA**  **- 20**  **11 -**  **1382 Directorate Identifier**  **2011 -**  **SW -**  **053 -** **AD** Comments have been received in response to : **“ Final rule; requ**  **est for comments,”** Airworthiness Directive (AD) Docket and Directorate Identifier entered above. (Project engineer: Please review any comments to determine if additional action is warranted. Once you have made your determination, please fill in the com menter(s) name(s) and check the appropriate response below. Include additional information following the appropriate response, if necessary. Then **include your name and**  **the date**  in the spaces provided, and return it to the AD directorate focal. The FAA has reviewed comment(s) related to the above FAA Docket that we re ceived from: William E. Taylor, Enstrom Helicopter Corporation **(Please check on**  **e**

**)** These comments **have not** been found to contain any information to warrant reconsideration or change of this AD. These comments **have** been found to contain information that warrants consideration of additional regulatory

action. 

### (SEE Airworthiness Directives Manual **FAA -**  **IR -**  **M -**  **8040.1 FOR ADDITIONAL ACTION.)**

_ _____G. Michalik

_____ March 13, 2012

__ Name: Date:

(This form is part of the official docket file for this AD action.)
<PAGE>   1

                                                                    EXHIBIT 23.3

                          INDEPENDENT AUDITORS' CONSENT




The Board of Directors
Harbinger Corporation:


We consent to the use of our report dated February 19, 1997 relating to the
combined statements of operations, shareholders' equity (deficit), and cash
flows of SupplyTech, Inc. and SupplyTech International, LLC. for the year ended
December 31, 1995 included in Harbinger Corporation's Report on Form 8-K/A
Amendment No. 1 filed on March 18, 1997 and Harbinger Corporation's Current
Report on Form 8-K filed on July 1, 1997 and incorporated by reference to this
Form 10-K for the fiscal year ended December 31, 1997.




                                             Ciulla, Smith & Dale, LLP



Southfield, Michigan
March 26, 1998







                                       80
### IN THE

TENTH COURT OF APPEALS

No. 10

- 12

- 00379

- CV

MARGARET ELAINE WALK ER

, Appellant

v.

GUADALUPE VASQUEZ, S R., INDIVIDUALLY,

AND AS REPRESENTATIV E OF THE ESTATE

OF SILVIA VASQUEZ, D ECEASED, GUADALUPE

VASQUEZ, JR., VERONI CA VASQUEZ, BLANCA

VASQU EZ AND ROGELIO VASQU EZ

, Appellee s

From the 40th District Court

Ellis County, Texas

Trial Court No. 82966

MEMORANDUM OPINION

The parties have filed an agreed motion in which they ask this Court to vacate

the trial court's judgment, remand the case back to the trial court, and dismiss the

appeal. The parties have reached an agreement to settle their differences in the

underlying proceeding.Walker v. Vasquez Page 2

Because we have no authority to vacate the trial court’s judgment

, remand the

case, and dismiss the appeal, we grant the motion in part. See T EX

. R. A PP

. P . 42.1(a)(2);

43.2.

The trial court's judgment dated July 20, 2012 is set aside without regard to the

merits and is remanded to the trial court for further proceedings consistent with the

settlement agreement. T EX

. R. A PP

. P . 42.1(a)(2)(B).

There being no agreement of the parties as to costs, it is further ordered that costs

of this appeal are taxed against Margaret Elaine Walker. Id . (d).

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Just ice Davis, and

Justice Scoggins

Set aside and remanded

Opinion delivered and filed November 8, 2012

[CV06]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<CIK> 0000945633
<NAME> UNITED STATIONERS SUPPLY CO
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          18,993
<SECURITIES>                                         0
<RECEIVABLES>                                  275,993
<ALLOWANCES>                                    12,561
<INVENTORY>                                    607,682
<CURRENT-ASSETS>                               914,531
<PP&E>                                         286,395
<DEPRECIATION>                                 118,851
<TOTAL-ASSETS>                               1,279,903
<CURRENT-LIABILITIES>                          498,983
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         3,721
<OTHER-SE>                                     402,288
<TOTAL-LIABILITY-AND-EQUITY>                 1,279,903
<SALES>                                      3,393,045
<TOTAL-REVENUES>                             3,393,045
<CGS>                                        2,830,968
<TOTAL-COSTS>                                2,830,968
<OTHER-EXPENSES>                               389,315
<LOSS-PROVISION>                                 6,657
<INTEREST-EXPENSE>                              29,195
<INCOME-PRETAX>                                143,567
<INCOME-TAX>                                    60,158
<INCOME-CONTINUING>                             83,409
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    83,409
<EPS-BASIC>                                       2.40
<EPS-DILUTED>                                     2.37


</TABLE>
----

**EXHIBIT 13.B**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Annual Report of Petaquilla Minerals Ltd. (the “Company”) on amended Form 20-F for the 13 months ended May 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassam Moubarak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

|        |        |        |                                                                                                                                                             |
|--------|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 1.     |   | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
|   |   |   |                                                                                                                                                        |
|   | 2.     |   | The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.       |

 

 

|                               |        |
|-------------------------------|--------|
| /s/ Bassam Moubarak           |   |
| Bassam Moubarak               |
| (principal financial officer) |

 

Dated:  Novebmer 25, 2008

 

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

----
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Swift Energy
Income Partners 1986-D, Ltd.'s balance sheet and statement of operations con-
tained in its Form 10-Q for the quarter ended June 30, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   JUN-30-1997
<CASH>                                         1,041
<SECURITIES>                                   0
<RECEIVABLES>                                  198,017
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               199,058
<PP&E>                                         12,898,885
<DEPRECIATION>                                 (10,608,332)
<TOTAL-ASSETS>                                 2,489,611
<CURRENT-LIABILITIES>                          81,884
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     2,282,446
<TOTAL-LIABILITY-AND-EQUITY>                   2,489,611
<SALES>                                        105,760
<TOTAL-REVENUES>                               107,633
<CGS>                                          0
<TOTAL-COSTS>                                  96,229<F1>
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                (18,847)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (18,847)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (18,847)
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
<FN>
<F1>Includes lease operating expenses, production taxes and depreciation,
depletion and amortization expense.  Excludes general and administrative and
interest expense.
</FN>
        


</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                                        <C>
<PERIOD-TYPE>                                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                          12,600
<SECURITIES>                                         0
<RECEIVABLES>                                   29,600
<ALLOWANCES>                                         0
<INVENTORY>                                     67,300
<CURRENT-ASSETS>                               129,000
<PP&E>                                       1,135,500
<DEPRECIATION>                               (424,600)
<TOTAL-ASSETS>                                 856,700
<CURRENT-LIABILITIES>                          227,600
<BONDS>                                        331,100
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      1,800
<COMMON>                                         1,100
<OTHER-SE>                                     267,000
<TOTAL-LIABILITY-AND-EQUITY>                   856,700
<SALES>                                         62,700
<TOTAL-REVENUES>                                62,700
<CGS>                                           40,500
<TOTAL-COSTS>                                   61,600
<OTHER-EXPENSES>                               (6,400)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              10,500<F1>
<INCOME-PRETAX>                                (3,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (3,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,000)
<EPS-PRIMARY>                                    (.04)
<EPS-DILUTED>                                    (.04)
<FN>
<F1>Net of interest income of $0.3 million.
</FN>
        

</TABLE>
FY2002 10K Exhibit 10.38





                         Exhibit 10.38 


                                  * Confidential treatment requested



Western Regional Office

21700 Oxnard Street

Suite 1900

Woodland Hills, CA  91367












November 15, 2001

	
Freddie

                 Mac
	Steven M. Majerus

Vice President Capital Markets

E-Loan, Inc.

5875 Arnold Road

Dublin, CA  94568


	

	

	

	

	



Re:Master Commitment #[ ** ]

Master Agreement #[ ** ]

Seller/Servicer #[ ** ]



Dear Mr. Becker:

Enclosed is an amended page(s) (the "Amendment") to the above-referenced
Mater Commitment (the "Agreement").  This Amendment changes the
following:




	
Master Commitment/ Master Agreement
Attachment
	
Title
	
Section(s)

Paragraph(s)
	
Page(s)

	
Master Commitment
	
Required Delivery Date
	
I.7
	
2





Please replace the appropriate page of the Agreement with the enclosed
page.

 

If you have any questions, please contact Ruth Kuizon, Contract Specialist at
(818) 710-3060.

Sincerely,

/s/ 

Ruth Kuizon

Contract Specialist






                                  * Confidential treatment requested


Master Commitment Amount.  The dollar amount of this Master
Commitment shall be [ ** ] ("Master Commitment Amount").

5.Delivery.  Mortgages shall not be delivered by Originator to
Freddie Mac under this Master Commitment.  In order for Mortgages to be
delivered to Freddie Mac, Originator must sell the Mortgages to Direct Seller
for delivery under the Direct Seller MC.  Mortgages originated by Originator and
delivered under the Direct Seller MC will be applied toward the Master
Commitment Amount.

6.Minimum Servicing Spread.  The Minimum Servicing Spread for
Mortgages sold pursuant to the terms of this Master Commitment shall be [ **
]basis points ([ ** ]).

7.Required Delivery Date.  The sale of Mortgages to Freddie Mac
through Direct Seller under the terms of this Master Commitment is mandatory and
all deliveries shall be made by February 28, 2002.

8.Purchase Tolerance/Pair-off.  Purchase by Freddie Mac of at
least 90 percent of the Master Commitment Amount, will constitute fulfillment by
Seller of the purchase requirements under this Master Commitment.  In addition,
Freddie Mac shall purchase Mortgages otherwise eligible for purchase with an
aggregate unpaid principal balance not to exceed 100 percent of the Master
Commitment Amount.  Such purchase tolerances shall apply notwithstanding the
purchase tolerances set forth in Section 11.5 of the Guide.

9.Required Spreads.  The Required Spreads for Mortgages sold by
Direct Seller to Freddie Mac under the Guarantor Program or Multilender Program
are:



	
15-year Fixed-rate Mortgages
	
[ ** ]basis points

(.[ ** ])

	
20-year Fixed rate Mortgages
	
[ ** ]basis points

(.[ ** ])

	
30-year Fixed rate Mortgages
	
[ ** ]basis points

(.[ ** ])






These Required Spreads reflect Seller's participation in Freddie Mac's Gold
Remittance Cycle.

Originator agrees to provide Direct Seller with the Required Spreads stated
above when selling Mortgages to Direct Seller for delivery to Freddie Mac under
the Enhanced AOT Offering.


                                  * Confidential treatment requested
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1100 Blood pressure alarm. ( a ) *Identification.* A blood pressure alarm is a device that accepts the signal from a blood pressure transducer amplifier, processes the signal, and emits an alarm when the blood pressure falls outside a pre-set upper or lower limit.
( b ) *Classification.* Class II (performance standards).
' 

"1k_ ~~t..()r-T~~-

ftS'l -z.-z.-S l c~ ,.tcu r- er\. ~\ ""'-q,t A--ef1d>ov. 

;; 

''-' '\J .. ~~n~ -ct· - ·~LL~~-\,.,.ee_ __ ~t (\\-"' 

I \N t_~t,r--- ~~~ .. '-'~_.\, &f(tt/a5 

. ~,Q\412-_L .,~_,.,·""~-~c~ \ l Tu {_c,l{2_~'\ s·c-~d.~e ~C)~t 

L'a~~- ~a.""'-· _g_1.d~t~L.e .e.. .Q \ ~lil-. f_Jl)~~f-<rtdJc-.t-l 

fa_(£, ~__e-~ I'Lt-f-~6_~;:;_,J.: _ _s:z..j or·T'l:. c_. c, P. 

l"'"' ,'{N_ l/R~orahk tov- .-t: ~'- l) l 

za,c "' c;l&-l _·cth ... _o,_b; • ::'1~ 

t=l-Sif'r~cn~-~ -4~v.:t£c;£__~ Vtc~r ~~hat< S' (Vf€J.c;..l (<:_ 

t::L-l ( ~t... c.-c.~ ·~~(.__('ff~~< , B_ft.!.1.L~ CV-r I ~'!(!!f.~C£ t 

iS L 00 00 0 :fhc._ta ~ ~ ~~ l t~~\d.cl_b:.!J.~r=-~ Ni?._ ~ t"~.e ' ·- . · {)f'~...JtrhA.l 

~~~~ _ ~l<-b ~l--:4.~.h.Q-.c..<QJJ._Ia~-~~~~-o~ 

~~---- c..-.lL~_I_lO -b;ll~~ Fl ~~s-~ s ~-'~ t>C.t- 0 F- ~() l t4 . 

~l1tc...lA &;va~ic!_®:o ~du.c.c... ~ .bo~ s: l~C., ,+ ~~o 

n .. .;-- £u_ "Z- . i~l-4' Clc.J.<.\ . c.~.._, <>-L~. f~U.::.L.t "" '~~\ 

::GU\L Ca:v..~r--~ t:Pu • ' so . (O~Qf'""" b.c.!-~b-· ~~~jll}ct"-

t-lo<i- ~ 4a.l_f-v-~t ~k ""~"r f2"-4-"' f ~ft~·c.flv<- ~ r £\.(l r ~l 

h~Le.;_~~~-. 

M<'L'~~:" P-v:il-~(l~_..)- ~( r..t..ll~f_a~ ~w-~J'!J ~ 

~-""--QI,J'~- i:J~ -hr-e._q.o..t~l.~-~<' '-'l...,ckr· {U--'lOtLl"-:''1__ o.f-f~v.''1-• 

-e-tl~ s. ~" l~ Oec.l~ "\)"' . ' .. .. I 

~ ~C[E~VED ~~ -~.,/::] /:;::::? ~ _ 7-/R-15 

com OF CRII\Jlii\!Al AIPPIEAl~ 

. ..,.__ ('\ l "815 g_ t.c.Ctt~zl.._~ L_b_LX~"- P Ju k. Ill f---("'"' A o~t \;)C1 "" .) L1 

o~u~\_(a~~r--~ ::r .... \.1 ~T-2F0 )®~Ateos~~, C~~rk ~-o .. BuY- ~-"'6 s1 ..( 

~~u~l r~ ')5'2&b : -. 

: . -. .- ' < 

. 

. . 

I 

-, 

------- \ 

~
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5445 Intravascular administration set, automated air removal system. ( a ) *Identification.* An intravascular administration set, automated air removal system, is a prescription device used to detect and automatically remove air from an intravascular administration set with minimal to no interruption in the flow of the intravascular fluid. The device may include an air identification mechanism, software, an air removal mechanism, tubing, apparatus to collect removed air, and safety control mechanisms to address hazardous situations.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Provide an argument demonstrating that all reasonably foreseeable hazards have been adequately addressed with respect to the persons for whose use the device is represented or intended and the conditions of use for the device, which includes the following: ( i ) Description of the device indications for use, design, and technology, use environments, and users in sufficient detail to determine that the device complies with all special controls.
( ii ) Demonstrate that controls are implemented to address device system hazards and their causes.
( iii ) Include a justification supporting the acceptability criteria for each hazard control.
( iv ) A traceability analysis demonstrating that all credible hazards have at least one corresponding control and that all controls have been verified and validated in the final device design.
( 2 ) Appropriate software verification, validation, and hazard analysis must be performed.
( 3 ) The device parts that directly or indirectly contact the patient must be demonstrated to be biocompatible.
( 4 ) Performance data must demonstrate the sterility of fluid path contacting components and the shelf life of these components.
( 5 ) The device must be designed and tested for electrical safety and electromagnetic compatibility (EMC).
( 6 ) Nonclinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Device system and component reliability testing must be conducted.
( ii ) Fluid ingress protection testing must be conducted.
( iii ) Testing of safety controls must be performed to demonstrate adequate mitigation of hazardous situations, including sensor failure, flow control failure, improper device position, device malfunction, infusion delivery error, and release of air to the patient.
( 7 ) A human factors validation study must demonstrate that use hazards are adequately addressed.
( 8 ) The labeling must include the following: ( i ) The device's air identification and removal response time.
( ii ) The device's minimum air volume identification sensitivity.
( iii ) The minimum and maximum flow rates at which the device is capable of reliably detecting and removing air.
( iv ) Quantification of any fluid loss during device air removal operations as a function of flow rate.
[79 FR 28406, May 16, 2014]